• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva plans competitor for Mylan’s EpiPen

September 12, 2016 By Sarah Faulkner

Teva, MylanTeva Pharmaceutical (NYSE:TEVA) said last week that it hopes to win U.S. approval for its version of Mylan‘s (NSDQ:MYL) EpiPen by late 2017 or early 2018.

Mylan’s EpiPen holds an estimated 94% market share in the U.S.; an alternate device from Teva could threaten the product’s dominance.

Teva’s application for its epinephrine injector has been in question since February, when the FDA cited “major deficiencies” with the device.

“We requested a meeting with the FDA,” Sigurdur Olafsson, Teva’s head of global generic medicines, said in a webcast overview of the company’s generics medicines business.

Teva did not get an immediate response from the federal safety watchdog, but after “the media attention in the last 2 weeks, the FDA has come back to us and we will have a meeting very, very quickly,” he said.

Mylan has come under fire in recent weeks for raising the price of the EpiPen nearly 500% since 2008, from $100 to as much as $600 today. In late August, Sens. Amy Klobuchar (D-Minn.) and Charles Grassley (R-Iowa) pressed Mylan to release a cost analysis of the device. Klobuchar also penned a letter to the U.S. Federal Trade Commission to investigate whether Mylan violated antitrust laws.

Last week the US Senate investigations panel launched a “preliminary inquiry” into the company’s pricing of the EpiPen.

Teva’s announcement came on the same day that Grassley, the chair of the US Senate Judiciary Committee, called Mylan’s response to his call for a cost analysis “incomplete.”

“It’s an incomplete response and wouldn’t satisfy my constituents who are upset about the EpiPen price increases. It doesn’t provide the full picture that I requested, and it doesn’t answer all of my questions,” Grassley said in prepared remarks.

Amid the criticism, Mylan CEO Heather Bresch maintained that the price increases are justified because of improvements Mylan made to the device. The company announced in August that they would expand existing patient assistance programs and develop a generic that would cost around $300 for a pair of injectors.

Mylan’s shares dropped 10% to $42.64 apiece when the criticism began in August. Since then, shares have slowly but steadily declined. The stock was trading at $40.60 per share in mid-morning activity today, up 1.78%.

Material from Reuters was used in this report.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Mylan, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS